1. Search Result
Search Result
Results for "

3-methylglutaryl

" in MedChemExpress (MCE) Product Catalog:

36

Inhibitors & Agonists

1

Biochemical Assay Reagents

14

Peptides

10

Natural
Products

1

Recombinant Proteins

4

Isotope-Labeled Compounds

5

Antibodies

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-17379
    Atorvastatin hemicalcium salt
    Maximum Cited Publications
    65 Publications Verification

    CI-981; Atorvastatin hemicalcium

    HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis Metabolic Disease Inflammation/Immunology Cancer
    Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, with blood-brain barrier permeability. Atorvastatin hemicalcium salt has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively [3] .
    Atorvastatin hemicalcium salt
  • HY-134124

    Reactive Oxygen Species (ROS) Metabolic Disease
    Glutathione ethyl ester is a cell-permeable GSH donor and provides an efficient supply of GSH to the oocyte. Glutathione ethyl ester shows positive effect on the in vitro production of embryos by enhancement of the antioxidative defense .
    Glutathione ethyl ester
  • HY-100793
    SR12813
    5+ Cited Publications

    GW 485801

    Pregnane X Receptor (PXR) HMG-CoA Reductase (HMGCR) Autophagy Metabolic Disease
    SR12813 (GW 485801) is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, with an IC50 value of 0.85 μM . SR12813 is also an efficient agonist of human pregnane X receptor (hPXR). SR12813 can strongly bind to hPXR but not to mouse PXR (mPXR) [3].
    SR12813
  • HY-P10272

    PTG-300

    Ferroportin Others
    Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .
    Rusfertide
  • HY-A0248A
    Polymyxin B1
    1 Publications Verification

    Bacterial Infection
    Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
    Polymyxin B1
  • HY-N0468
    Rebaudioside D
    1 Publications Verification

    FXR Acetyl-CoA Carboxylase Metabolic Disease
    Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
    Rebaudioside D
  • HY-114294A

    HMG-CoA disodium hydrate

    Biochemical Assay Reagents Metabolic Disease
    DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium hydrate is a disodium salt compound of HMG-CoA, is a intermediate of terpenes and ketone bodies. DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium also involves in ester metabolism in vivo, as a precursor for cholesterol synthesis, and regulates cholesterol synthesis by coupling LDL receptor .
    DL-3-Hydroxy-3-methylglutaryl coenzyme A disodium hydrate
  • HY-P1108A
    Astressin 2B TFA
    1 Publications Verification

    CRFR Neurological Disease Inflammation/Immunology
    Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 [3] .
    Astressin 2B TFA
  • HY-P1108
    Astressin 2B
    1 Publications Verification

    CRFR Neurological Disease Inflammation/Immunology
    Astressin 2B is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 [3] .
    Astressin 2B
  • HY-17379R

    CI-981 (Standard); Atorvastatin hemicalcium (Standard)

    Reference Standards HMG-CoA Reductase (HMGCR) Autophagy Ferroptosis Metabolic Disease Inflammation/Immunology Cancer
    Atorvastatin (hemicalcium salt) (Standard) is the analytical standard of Atorvastatin (hemicalcium salt). This product is intended for research and analytical applications. Atorvastatin hemicalcium salt (CI-981) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin hemicalcium salt inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively [3].
    Atorvastatin hemicalcium salt (Standard)
  • HY-113006

    Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    3-Methylglutarylcarnitine is a biomarker of disease associated with compromised mitochondrial energy metabolism .
    3-Methylglutarylcarnitine
  • HY-W414823

    LXR HMG-CoA Reductase (HMGCR) Metabolic Disease
    24,25-Epoxycholesterol is an oxysterol agonist of the liver X receptor that can inhibit the activity of 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase) in liver cells. 24,25-Epoxycholesterol regulates cholesterol metabolism in the liver .
    24,25-Epoxycholesterol
  • HY-P10143

    Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt

    MMP Others
    MMP-2/MMP-9 Substrate (Ac-Pro-Leu-Gly-[(S)-2-mercapto-4-methyl-pentanoyl]-Leu-Gly-OEt) is a synthetic chromogenic polypeptide substrate whose core structure mimics the cleavage sites of MMP-2 and MMP-9 (gelatinase A and B) in collagen. After being hydrolyzed by collagenase, MMP-2/MMP-9 Substrate reacts with 4,4'-dithiodipyridine or Ellman's Reagent via its thiol fragment to produce a product with ultraviolet absorption properties .
    MMP-2/MMP-9 Substrate
  • HY-A0248AS

    Isotope-Labeled Compounds Bacterial Infection
    Polymyxin B1-d7 TFA is the deuterium labeled Polymyxin B1 TFA (HY-A0248A). Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
    Polymyxin B1-d7 TFA
  • HY-106380

    HR 780

    HMG-CoA Reductase (HMGCR) Metabolic Disease
    Glenvastatin (HR 780) is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Glenvastatin can reduces plasma total cholesterol and phospholipid levels and liver cholesterol contents. Glenvastatin does not increase the contents of cholesterol and total bile acid in the gallbladder bile. Glenvastatin can be used for the research of hyperlipemia
    Glenvastatin
  • HY-19671

    SR-45023A; SR 9223i; SK&F-99085

    HMG-CoA Reductase (HMGCR) Apoptosis Cancer
    Apomine (SR-45023A) is an orally active antineoplastic agent that inhibits the mevalonate/isoprenoid pathway in cholesterol synthesis. Apomine can accelerate the degradation of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR). Apomine can also inhibit the growth of various types of cancer cells, including lung cancer, colon cancer, breast cancer, and skin cancer. Apomine is able to induce apoptosis in tumor cell lines derived from leukemia, colon cancer, liver cancer, ovarian cancer, and breast cancer .
    Apomine
  • HY-139951S

    Isotope-Labeled Compounds Others
    3-Hydroxy-3-methylglutaryl-Coenzyme A-d3 (ammonium) is the deuterium labeled 3-Hydroxy-3-methylglutaryl-Coenzyme A ammonium .
    3-Hydroxy-3-methylglutaryl-Coenzyme A-d3 ammonium
  • HY-P10563

    BHV-1100

    CD38 Cancer
    Noraramtide (BHV-1100) is an antibody recruitment molecule. Noraramtide can specifically bind to CD38 molecules to recruit natural killer (NK) cells. Noraramtide enhances the ability of NK cells to kill tumor cells through antibody-dependent cellular cytotoxicity (ADCC). This mechanism allows NK cells to more effectively recognize and eliminate tumor cells while avoiding mutual killing between NK cells. Noraramtide can be used for the study of autologous cancer immunity .
    Noraramtide
  • HY-P3066

    d(CH2)5Tyr(Et)VAVP

    Vasopressin Receptor Metabolic Disease
    SKF 100398 (d(CH2)5Tyr(Et)VAVP), an arginine vasopressin (AVP) analogue, is a specific antagonist of the antidiuretic effect of exogenous and endogenous AVP .
    SKF 100398
  • HY-135373

    Drug Metabolite Metabolic Disease Inflammation/Immunology
    Desfluoro-atorvastatin is an impurity of Atorvastatin . Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids .
    Desfluoro-atorvastatin
  • HY-101873S

    Isotope-Labeled Compounds HMG-CoA Reductase (HMGCR) Metabolic Disease Inflammation/Immunology
    Atorvastatin lactone-d5 is a deuterated form of Atorvastatin lactone (HY-101873). Atorvastatin lactone is a proagent form of atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor .
    Atorvastatin lactone-d5
  • HY-129149

    HMG-CoA Reductase (HMGCR) Metabolic Disease
    Ganoderic acid SZ is a natural product with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitory activity. Ganoderic acid SZ shows stronger activity than the positive control atorvastatin in inhibiting HMG-CoA reductase. Ganoderic acid SZ exhibits significant inhibition of yeast-derived α-glucosidase with IC50 values achieved at very low concentrations. Ganoderic acid SZ also exhibits cytotoxicity against K562 cells with IC?? values in the range of 10-20 μM .
    Ganoderic acid SZ
  • HY-P10828

    Virus Protease Infection Inflammation/Immunology
    MAPI is a polypeptide irreversible 3C cysteine protease (SV3CP) inhibitor. MAPI inhibits SV3CP by covalently binding its C-terminal Michael-acceptor extension to the active site thiol of SV3CP Cys 139. MAPI is promising for research of noroviruses infection .
    MAPI
  • HY-N13366

    Drug Metabolite Metabolic Disease
    3-Methylcrotonyl CoA is a key metabolic intermediate in the leucine degradation pathway, converted to 3-Methylglutaconyl CoA by 3-Methylcrotonyl CoA Carboxylase. Normally, 3-Methylglutaconyl CoA is catalyzed by 3-Methylglutaconyl-CoA Hydratase into 3-Hydroxy-3-methylglutaryl-CoA (HMG CoA). However, mutations in 3-Methylglutaconyl-CoA Hydratase lead to the accumulation of 3-Methylglutaconyl CoA, causing metabolic disorders associated with 3MGA-uria. 3-Methylcrotonyl CoA is useful for research into metabolic diseases related to the leucine degradation pathway .
    3-Methylcrotonyl CoA
  • HY-117219

    Cytochrome P450 HMG-CoA Reductase (HMGCR) Endogenous Metabolite Metabolic Disease
    SKF 104976 is a 3,2-carboxylic acid derivative with potent 14-alpha-demethylase (14 alpha DM) inhibitory activity. SKF 104976 inhibited 14 alpha DM activity by 50% at 2 nM in Hep G2 cell extracts. SKF 104976 inhibited the incorporation of [14C]acetate into cholesterol in intact cells at similar concentrations, accompanied by accumulation of lanosterol, and resulted in a 40-70% decrease in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) activity. SKF 104976 did not affect the uptake and degradation of low-density lipoprotein in Hep G2 cells, indicating that HMGR and low-density lipoprotein receptor activities are not coordinately regulated under these conditions. The inhibitory effect of SKF 104976 on HMGR activity remained unchanged even when the flux of carbon units in the sterol synthesis pathway was reduced by 80%. SKF 104976 did not inhibit HMGR activity under conditions where sterol synthesis was almost completely blocked by lovastatin .
    SKF 104976
  • HY-N0468R

    Reference Standards Acetyl-CoA Carboxylase FXR Metabolic Disease
    Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research [3].
    Rebaudioside D (Standard)
  • HY-N15097

    HMG-CoA Reductase (HMGCR) Infection Inflammation/Immunology
    Dihydrocompactin, an antifungal metabolite, is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMG-CoA reductase) from Penicillium citrinum .
    Dihydrocompactin
  • HY-117581

    6-Oxo Simvastatin; Iso-simvastatin-6-one

    HMG-CoA Reductase (HMGCR) Metabolic Disease
    L-669,262, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, with an IC50 of 0.10 ng/mL for rat liver HMG-CoA .
    L-669,262
  • HY-135375

    Drug Metabolite Metabolic Disease Inflammation/Immunology
    O-Methyl Atorvastatin (hemicalcium) is an impurity of Atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, has the ability to effectively decrease blood lipids .
    O-Methyl Atorvastatin calcium
  • HY-101873R

    Reference Standards HMG-CoA Reductase (HMGCR) Metabolic Disease Inflammation/Immunology
    Atorvastatin lactone (Standard) is the analytical standard of Atorvastatin lactone. This product is intended for research and analytical applications. Atorvastatin lactone is a proagent form of atorvastatin. Atorvastatin is an orally active 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor .
    Atorvastatin lactone (Standard)
  • HY-113725

    HMG-CoA Reductase (HMGCR) Others
    L 668411 is a β-lactone inhibitor with activity against 3-hydroxy-3-methylglutaryl-CoA synthase and cholesterol biosynthesis. L 668411 inhibits rat liver cytosolic 3-hydroxy-3-methylglutaryl-CoA synthase and [14C] acetate incorporation into sterols in cultured Hep G2 cells, and the inhibition appears to be irreversible in cells but reversible in cultured cells and animals.
    L 668411
  • HY-N18288

    Insecticide Infection
    6''-O-(3'''-Hydroxy-3'''-methylglutaryl) vitexin is an orally active flavonoid glycoside and insecticide that can be isolated from the twigs of Eleusine coracana. 6''-O-(3'''-Hydroxy-3'''-methylglutaryl) vitexin exhibits distinct antifeedant activity against Nilaparvata lugens (brown planthopper) nymphs and effectively inhibits their feeding behavior. 6''-O-(3'''-Hydroxy-3'''-methylglutaryl) vitexin can serve as a plant-derived natural defense substance for regulating pest behavior and investigating potential control mechanisms of agricultural pests .
    6''-O-(3'''-Hydroxy-3'''-methylglutaryl) vitexin
  • HY-P2592

    Cholecystokinin Receptor Others
    Ro 23-7014 is an appetite suppressant. Ro 23-7014 is an analog of cholecystokinin (CCK-7) .
    Ro 23-7014
  • HY-125628

    Endogenous Metabolite Infection
    Kahalalide A is an anti-mycobacterial compound with antimicrobial activity. Kahalalide A is derived from the marine mollusk Elysia rufescens. Kahalalide A has attracted extensive attention in natural product research due to its potential medicinal value .
    Kahalalide A
  • HY-100793R

    GW 485801 (Standard)

    Pregnane X Receptor (PXR) HMG-CoA Reductase (HMGCR) Reference Standards Autophagy Metabolic Disease
    SR12813 (Standard) is the analytical standard of SR12813 (HY-100793). This product is intended for research and analytical applications. SR12813 (GW 485801) is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, with an IC50 value of 0.85 μM . SR12813 is also an efficient agonist of human pregnane X receptor (hPXR). SR12813 can strongly bind to hPXR but not to mouse PXR (mPXR) [3].
    SR12813 (Standard)
  • HY-A0248AS1

    Isotope-Labeled Compounds Bacterial Infection
    Polymyxin B1-D-Leu-d7 TFA is the deuterium labeled Polymyxin B1 (HY-A0248A). Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
    Polymyxin B1-D-Leu-d7 TFA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: